Breaking News

How to leverage the gut-skin axis to address health conditions

Food supplements: a better way to utilise the body’s microbiome? Stuart J. Ashman, CEO, and Dr Catherine O’Neill, CSO, SkinBioTherapeutics, investi...

DuPont enters microbiome therapy collaboration with MRM Health

MRM has raised more than $15m to advance its clinical and preclinical development programmes

Kaleido joins forces with Janssen on microbiome metabolic therapies

Janssen and Kaleido have agreed to explore the potential of microbiome metabolic therapies to prevent onset of childhood allergy and other atopic,...

Exponential growth on the cards for the microbiome industry

The microbiome market could be as big as biotech in the next 20 years, reports Dr Isabelle de Cremoux, CEO and Managing Partner, Seventure Partners

LNC Therapeutics forms advisory board for Christensenella research

The gut microbiome-based drug research and discovery specialist has chosen experts to advise the future of its Christensella R&D programme

New microbiome specialist raises $82m and partners with Thermo Fisher

Arranta Bio will have access to Thermo Fisher’s full suite of products and services and will provide materials to Thermo Fisher for use in gene the...

Call to cut Indian child deaths from pneumonia and diarrhoea

Lack of access to life-saving treatment and prevention measures such as vaccination programmes is costing the lives of many Indian children

Tillotts signs IBD research agreement

Discovery efforts with LabGenius to identify and develop new drug candidates for the treatment of inflammatory bowel diseases

Berberine enhances antibiotic treatment of Helicobacter pylori

<i>Helicobacter pylori</i> are Gram-negative bacteria that inhabit the gastric mucosa and are associated with peptic ulcers and gastric malignancy

Opioid-induced constipation – naloxegol

About half of all patients taking opioids commonly experience constipation

Collaboration to develop novel microbial therapy for UC

Microbiotica has entered into an agreement with the University of Adelaide as part of its programme to develop a defined bacterial product for ulce...

Inflammatory bowel disease – vedolizumab

Although Crohn’s disease and ulcerative colitis are the two most common forms of inflammatory bowel disease, treatment options remain less than ideal

Microbiotica enters into microbiome collaboration with Genentech

Microbiotica, a leading player in microbiome-based therapeutics, has entered into a multi-year strategic collaboration with Genentech, a member of...

Obesity – lorcaserin

With the growing incidence of obesity there is a real need for pharmaceutical assistance for losing weight in patients who are unable (or unwilling...